There are currently 279 active clinical trials seeking participants for Cancer research studies. The states with the highest number of trials for Cancer participants are California, Texas, New York and Florida.
Avera Cancer Sequencing and Analytics Protocol (ASAP)
NCT05142033
Recruiting
The purpose of this study is to understand the breadth of molecular characteristics present in participants cared for in a large integrated, community-based health care system. Using comprehensive genomic profiling and proteomics, the investigators seek to identify the underlying genomic drivers of premalignant or malignant conditions in participants across different stages of disease development and cancer types. Comprehensive molecular profiling will consist of somatic tumor testing (tissue a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Avera Cancer Institute - Aberdeen, Aberdeen, South Dakota +1 locations
Conditions: Cancer, Cancer Diagnosis, Early Detection of Cancer, Breast Cancer, Lung Cancer, Colon Cancer, GI Cancer, Gynecologic Cancer, Ovarian Cancer, Endometrial Cancer, CNS Cancer, Hematologic Cancer
Register for Updates
Mindful Waiting Room
NCT05433636
Recruiting
This will be a single-site, five-arm, parallel group randomized control trial involving patients seeking integrative healthcare. Four different styles of 5-minute, audio-recoded mindfulness practices delivered in the clinic waiting room will be compared with a 5-minute audio-recording about integrative healthcare. A secondary sub-analysis will investigate the most effective mindfulness practice style for patients presenting at the clinic with elevated anxiety, depression, or pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Anxiety State, Depressive State, Pain, Nausea, Fatigue, Cancer
Register for Updates
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
NCT05378425
Recruiting
This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without pembrolizumab, in patients with advanced solid malignancies (i.e., locally advanced or metastatic).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/25/2024
Locations: City of Hope, Duarte, California +4 locations
Conditions: Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
Register for Updates
mychoiceTM Implementation With Medical Oncology Patients
NCT06222242
Recruiting
This is a pragmatic, non-randomized mixed-methods evaluation study designed to evaluate the feasibility and acceptability of delivering the mychoiceTM tool to new Medical Oncology patients as well as to more deeply explore its value to patients in their discussion with their provider about clinical trials as a treatment option over the course of their oncology treatment (Effectiveness).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Cancer
Register for Updates
Vincere Biobank Research Protocol
NCT05954299
Recruiting
The Vincere Biobank aims to make quality biospecimens and associated clinical data available for research studies related to advancing medicine and improving care for patients, including cancer screening, treatment, and care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2023
Locations: Vincere Cancer Center, Scottsdale, Arizona
Conditions: Cancer
Register for Updates
Positron Emission Tomography (PET) Imaging of Thrombosis
NCT03830320
Recruiting
The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasive alternative to the current standard-of-care methods.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
12/01/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Atrial Fibrillation, COVID-19, Cancer, Thrombosis
Register for Updates
Screening for Atrial Fibrillation in Patients With Cancer: A Pilot Randomized Controlled Clinical Trial
NCT05784766
Recruiting
Patients with cancer have a higher incidence of AF but despite the higher incidence of AF in the cancer population, there are no randomized controlled trials (RCTs) for AF screening in this population. RCTs of AF screening in the general population have shown that screening can effectively detect AF earlier, and helps to identify candidates for appropriate anticoagulation that may lead to improvement in clinical outcomes.
Gender:
ALL
Ages:
Between 65 years and 90 years
Trial Updated:
11/20/2023
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Cancer
Register for Updates
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
NCT04283539
Recruiting
This protocol is a prospective, observational study of participants receiving immunotherapy (checkpoint inhibitors, CPI) for cancer therapy, testing the hypothesis that patients with immune related cutaneous adverse events (ircAEs) have unique immunologic endotypes associated with polarized immune responses.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2023
Locations: National Jewish Health, Denver, Colorado +2 locations
Conditions: Cancer
Register for Updates
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
NCT03213002
Recruiting
The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM). Capecitabine is an oral chemotherapy that is given to patients with other types of cancer. The study will evaluate whether the dosage of 1500 mg/m2 of capecitabine is tolerable after radiation, when taken along with temozolomide. It wi... Read More
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
11/07/2023
Locations: Lenox Hill Brain Tumor Center, New York, New York
Conditions: Glioblastoma Multiforme (GBM), Glioblastoma, Glioma of Brain, Glioblastoma, Adult, Brain Tumor, Brain Tumor, Primary, Brain Tumor Adult, Cancer, Brain Cancer
Register for Updates
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
NCT05094804
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: HonorHealth Research Institute, Scottsdale, Arizona +2 locations
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Register for Updates
Device Feasibility and Acceptability to Improve Insomnia in Cancer
NCT05875129
Recruiting
Sleep disruption is common among young adult cancer survivors for a variety of reasons. Cognitive behavioral therapy for insomnia (CBT-I) has been shown to improve chronic sleep disorders. This project will test the feasibility and acceptability of a new voice-activated virtual assistant (VAVA) device to deliver CBT-I to improve sleep among young adult cancer survivors with chronic sleep disorders.
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
10/04/2023
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Cancer, Insomnia Chronic
Register for Updates
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: City of Hope, Duarte, California +11 locations
Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
Register for Updates